Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. The MD is manufactured by B-ON, and the company asserts that the device can measure a user’s electrocardiogram (EKG) activity, blood pressure,...